Why MD Sermorelin exists

Why the antibody question?

My expectation for sermorelin was a story about a pituitary signal and childhood growth. The antibodies in the Chen study disturbed that neat account: nearly everyone developed them, yet their presence failed to correlate with growth. The longer childhood follow-up made the puzzle more substantial.

I would rather wrestle with that unresolved clinical detail than settle for the adjective “natural.” It leaves room for a body to respond in several ways at once, and for a useful medicine to have a more complicated history than its reputation suggests.

MD Sermorelin’s scope

I’m no physician. MD Sermorelin names this website; those letters carry no professional status. This is a place for commentary on published hormone research, with no facility for prescribing, purchasing products, arranging deliveries or booking appointments.

An antibody result can absorb my curiosity without telling anyone whether a treatment fits their health. These pages provide no medical advice, and an actual care decision requires a licensed professional’s assessment. I can challenge an overbroad claim in public; a person’s health calls for a clinical assessment.

Former approval, current compounding

The former product received FDA approval in 1990 for diagnostic use and in 1997 for treatment of pediatric idiopathic GH deficiency. Commercial production ended in 2008 for business reasons, with formal FDA withdrawal published in 2013. Its pediatric clinical history remains distinct from the adult wellness uses discussed today.

Current U.S. patient care uses a clinician-prescribed compounded preparation, which has no FDA approval. The FDA’s interim Section 503A policy (finalized in January 2025) provides the compounding framework: sermorelin is treated as a long-standing Category 1 bulk substance, for which the agency does not intend enforcement action under that policy. State and treatment limits still apply, and the clinician may decline an individual case.

The 2025 WADA list separately prohibits sermorelin in and out of competition. It is not a DEA-scheduled controlled substance. These are different regulatory questions, each with its own scope.

Corrections

An error about antibody function would be especially unwelcome here. The contact page sets out the information needed to identify a source problem: the page, the passage and the publication that supports a correction. A better explanation of the puzzle would be welcome; I’ll need more than confidence to be persuaded.